A multi-arm trial investigating HS-110 in combination with other immunotherapies in patients with non-small cell lung cancer

Trial Profile

A multi-arm trial investigating HS-110 in combination with other immunotherapies in patients with non-small cell lung cancer

Planning
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Viagenpumatucel-L (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Dec 2017 According to a Heat Biologics media release, the company has received written responses from the U.S. Food and Drug Administration (FDA) following its Type C meeting regarding the clinical trial design. Trial design details and next steps are expected to be announced in 2H 2018.
    • 05 Feb 2015 New trial record
    • 02 Feb 2015 According to a Heat Biologics media release, this trial is expected to start in the first half of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top